Jump to main content
Jump to site search


A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Author affiliations

Abstract

An HCBP1 peptide–ruthenium conjugate (Ru–β-Ala-FQHPSFI) as a potential candidate for targeted therapy of hepatoma was synthesized. Ru–β-Ala-FQHPSFI shows drastically enhanced cytotoxicity and high selectivity for hepatoma cells versus noncancer liver cells. Raman imaging shows that this peptide-based drug can be taken up well by the hepatoma cells compared with the bare ruthenium complex (Ru) and the opposite sequence peptide–ruthenium conjugate (Ru-β-Ala-IFSPHQF). This study presents a new strategy for the construction of tumor-targeting metal-based anticancer therapeutics.

Graphical abstract: A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Back to tab navigation

Supplementary files

Article information


Submitted
30 Sep 2019
Accepted
09 Dec 2019
First published
10 Dec 2019

Dalton Trans., 2020, Advance Article
Article type
Communication

A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Y. Wang, W. Qin, H. Shi, H. Chen, X. Chai, J. Liu, P. Zhang, Z. Li and Q. Zhang, Dalton Trans., 2020, Advance Article , DOI: 10.1039/C9DT03856F

Social activity

Search articles by author

Spotlight

Advertisements